Skip Nav Destination
Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL
Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome
Induction of blood-circulating bile acids supports recovery from myelosuppressive chemotherapy
Adult T-cell leukemia/lymphoma incidence rate in French Guiana: a prospective cohort of women infected with HTLV-1
Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results
Survival following allogeneic transplant in patients with myelofibrosis
Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases
Issue Archive
May 12 2020
In this Issue
Table of Contents
CLINICAL GUIDELINES
A user guide to the American Society of Hematology clinical practice guidelines
Ariel Izcovich,Adam Cuker,Robert Kunkle,Ignacio Neumann,Julie Panepinto,Menaka Pai,Matthew Seftel,Matthew C. Cheung,Richard Lottenberg,Michael Byrne,Robert Plovnick,Deirdra Terrell,Jennifer L. Holter-Chakrabarty,Benjamin Djulbegovic,Lisa K. Hicks,Wojtek Wiercioch,Robby Nieuwlaat,Holger J. Schünemann
TESTING ADVANCES
STIMULUS REPORTS
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Jillian F. Wise,Sigve Nakken,Chloé B. Steen,Daniel Vodák,Gunhild Trøen,Bjarne Johannessen,Ole Christian Lingjærde,Vera Hilden,Yngvild Nuvin Blaker,Baoyan Bai,Lars Birger Aasheim,Annika Pasanen,Susanne Lorenz,Anita Sveen,Ragnhild A. Lothe,Ola Myklebost,Sirpa Leppä,Leonardo A. Meza-Zepeda,Klaus Beiske,Michael S. Lawrence,Eivind Hovig,June Helen Myklebust,Erlend B. Smeland,Harald Holte
Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease
Clinical Trials & Observations
Matthew M. Hsieh,Melissa Bonner,Francis John Pierciey, Jr,Naoya Uchida,James Rottman,Laura Demopoulos,Manfred Schmidt,Julie Kanter,Mark C. Walters,Alexis A. Thompson,Mohammed Asmal,John F. Tisdale
CLINICAL TRIALS AND OBSERVATIONS
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
Clinical Trials & Observations
Sirpa Leppä,Judit Jørgensen,Anne Tierens,Leo Meriranta,Ingunn Østlie,Peter de Nully Brown,Unn-Merete Fagerli,Thomas Stauffer Larsen,Susanna Mannisto,Lars Munksgaard,Martin Maisenhölder,Kaija Vasala,Peter Meyer,Mats Jerkeman,Magnus Björkholm,Øystein Fluge,Sirkku Jyrkkiö,Knut Liestøl,Elisabeth Ralfkiaer,Signe Spetalen,Klaus Beiske,Marja-Liisa Karjalainen-Lindsberg,Harald Holte
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL
Clinical Trials & Observations
Sarit Assouline,Shen Li,Christian Gisselbrecht,Patrick Fogarty,Annette Hay,Eric van den Neste,Lois E. Shepherd,Norbert Schmitz,Tara Baetz,Armand Keating,Sue Robinson,Matthew Seftel,Caterina Stelitano,Marina S. Djurfeldt,Ralph Meyer,Bingshu E. Chen,Michael Crump
Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome
Clinical Trials & Observations
Je-Hwan Lee,Stefan Faderl,John M. Pagel,Chul Won Jung,Sung-Soo Yoon,Animesh D. Pardanani,Pamela S. Becker,Howard Lee,Jeongeun Choi,Kyoungjune Lee,Minkyoung Kim,Jorge E. Cortes
HEMATOPOIESIS AND STEM CELLS
Induction of blood-circulating bile acids supports recovery from myelosuppressive chemotherapy
Clinical Trials & Observations
Valgardur Sigurdsson,Youichi Haga,Hajime Takei,Els Mansell,Chizuko Okamatsu-Haga,Mitsuyoshi Suzuki,Visnja Radulovic,Mark van der Garde,Shuhei Koide,Svetlana Soboleva,Mats Gåfvels,Hiroshi Nittono,Akira Ohara,Kenichi Miharada
IMMUNOBIOLOGY AND IMMUNOTHERAPY
LYMPHOID NEOPLASIA
Activation of PERK-ATF4-CHOP pathway as a novel therapeutic approach for efficient elimination of HTLV-1–infected cells
Emi Ikebe,Sahoko Matsuoka,Kenta Tezuka,Madoka Kuramitsu,Kazu Okuma,Makoto Nakashima,Seiichiro Kobayashi,Junya Makiyama,Makoto Yamagishi,Seiichi Oyadomari,Kaoru Uchimaru,Isao Hamaguchi
Adult T-cell leukemia/lymphoma incidence rate in French Guiana: a prospective cohort of women infected with HTLV-1
Clinical Trials & Observations
Global Advances
Jill-Léa Ramassamy,Patricia Tortevoye,Balthazar Ntab,Béatrice Seve,Gabriel Carles,Dominique Gaquière,Yoann Madec,Arnaud Fontanet,Antoine Gessain
Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation
Clinical Trials & Observations
Monzr M. Al Malki,Dongyun Yang,Myriam Labopin,Boris Afanasyev,Emanuele Angelucci,Asad Bashey,Gérard Socié,Amado Karduss-Urueta,Grzegorz Helbig,Martin Bornhauser,Riitta Niittyvuopio,Arnold Ganser,Fabio Ciceri,Arne Brecht,Yener Koc,Nelli Bejanyan,Francesca Ferraro,Partow Kebriaei,Sally Mokhtari,Armin Ghobadi,Ryotaro Nakamura,Stephen J. Forman,Richard Champlin,Mohamad Mohty,Stefan O. Ciurea,Arnon Nagler
MYELOID NEOPLASIA
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
Clinical Trials & Observations
Sung Choe,Hongfang Wang,Courtney D. DiNardo,Eytan M. Stein,Stéphane de Botton,Gail J. Roboz,Jessica K. Altman,Alice S. Mims,Justin M. Watts,Daniel A. Pollyea,Amir T. Fathi,Martin S. Tallman,Hagop M. Kantarjian,Richard M. Stone,Lynn Quek,Zenon Konteatis,Lenny Dang,Brandon Nicolay,Parham Nejad,Guowen Liu,Vickie Zhang,Hua Liu,Meredith Goldwasser,Wei Liu,Kevin Marks,Chris Bowden,Scott A. Biller,Eyal C. Attar,Bin Wu
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results
Clinical Trials & Observations
Claude Gardin,Cécile Pautas,Elise Fournier,Raphaël Itzykson,Emilie Lemasle,Jean-Henri Bourhis,Lionel Adès,Jean-Pierre Marolleau,Jean-Valère Malfuson,Lauris Gastaud,Emmanuel Raffoux,Juliette Lambert,Thorsten Braun,Xavier Thomas,Sylvain Chantepie,Thomas Cluzeau,Stéphane de Botton,Céline Berthon,Nicolas Boissel,Nicolas Duployez,Christine Terré,Régis Peffault de Latour,Mauricette Michallet,Karine Celli-Lebras,Claude Preudhomme,Hervé Dombret
PLATELETS AND THROMBOPOIESIS
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
FVIII half-life extension by coadministration of a D′D3 albumin fusion protein in mice, rabbits, rats, and monkeys
Sabine Pestel,Hans-Wilhelm Beltz,Philipp Claar,Holger Lind,Marcel Mischnik,Elmar Raquet,Arna Andrews,Jason Simmonds,Vesna Tomasetig,Steven K. Dower,Anna Tjärnlund-Wolf,Stefan Schulte,Peter M. Schmidt,Thomas Weimer
TRANSFUSION MEDICINE
TRANSPLANTATION
BK virus–specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation
Eduardo Espada,Matthew P. Cheng,Haesook T. Kim,Ann E. Woolley,Jason I. Avigan,Edouard Forcade,Maria V. D. Soares,João F. Lacerda,Sarah Nikiforow,Mahasweta Gooptu,Rizwan Romee,Edwin P. Alyea,Philippe Armand,Corey S. Cutler,Vincent T. Ho,John Koreth,Joseph H. Antin,Robert J. Soiffer,Francisco M. Marty,Jerome Ritz
Survival following allogeneic transplant in patients with myelofibrosis
Clinical Trials & Observations
Krisstina Gowin,Karen Ballen,Kwang Woo Ahn,Zhen-Huan Hu,Haris Ali,Murat O. Arcasoy,Rebecca Devlin,Maria Coakley,Aaron T. Gerds,Michael Green,Vikas Gupta,Gabriela Hobbs,Tania Jain,Malathi Kandarpa,Rami Komrokji,Andrew T. Kuykendall,Kierstin Luber,Lucia Masarova,Laura C. Michaelis,Sarah Patches,Ashley C. Pariser,Raajit Rampal,Brady Stein,Moshe Talpaz,Srdan Verstovsek,Martha Wadleigh,Vaibhav Agrawal,Mahmoud Aljurf,Miguel Angel Diaz,Belinda R. Avalos,Ulrike Bacher,Asad Bashey,Amer M. Beitinjaneh,Jan Cerny,Saurabh Chhabra,Edward Copelan,Corey S. Cutler,Zachariah DeFilipp,Shahinaz M. Gadalla,Siddhartha Ganguly,Michael R. Grunwald,Shahrukh K. Hashmi,Mohamed A. Kharfan-Dabaja,Tamila Kindwall-Keller,Nicolaus Kröger,Hillard M. Lazarus,Jane L. Liesveld,Mark R. Litzow,David I. Marks,Sunita Nathan,Taiga Nishihori,Richard F. Olsson,Attaphol Pawarode,Jacob M. Rowe,Bipin N. Savani,Mary Lynn Savoie,Sachiko Seo,Melhem Solh,Roni Tamari,Leo F. Verdonck,Jean A. Yared,Edwin Alyea,Uday Popat,Ronald Sobecks,Bart L. Scott,Ryotaro Nakamura,Ruben Mesa,Wael Saber
Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis
Clinical Trials & Observations
Matthias Felber,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Colin G. Steward,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Karim Kentouche,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Anders Fasth,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Robert F. Wynn,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Ulrike Zeilhofer,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Veronika Haunerdinger,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Benjamin Volkmer,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Seraina Prader,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Bernd Gruhn,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Stephan Ehl,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Kai Lehmberg,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Daniel Müller,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Andrew R. Gennery,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Michael H. Albert,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Fabian Hauck,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Kanchan Rao,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Paul Veys,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Moustapha Hassan,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Arjan C. Lankester,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Jana Pachlopnik Schmid,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Mathias M. Hauri-Hohl,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),Tayfun Güngör,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID)
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases
Clinical Trials & Observations
Justine M. Kahn,Ruta Brazauskas,Heather R. Tecca,Stephanie Bo-Subait,David Buchbinder,Minoo Battiwala,Mary E. D. Flowers,Bipin N. Savani,Rachel Phelan,Larisa Broglie,Allistair A. Abraham,Amy K. Keating,Andrew Daly,Baldeep Wirk,Biju George,Blanche P. Alter,Celalettin Ustun,Cesar O. Freytes,Amer M. Beitinjaneh,Christine Duncan,Edward Copelan,Gerhard C. Hildebrandt,Hemant S. Murthy,Hillard M. Lazarus,Jeffery J. Auletta,Kasiani C. Myers,Kirsten M. Williams,Kristin M. Page,Lynda M. Vrooman,Maxim Norkin,Michael Byrne,Miguel Angel Diaz,Naynesh Kamani,Neel S. Bhatt,Andrew Rezvani,Nosha Farhadfar,Parinda A. Mehta,Peiman Hematti,Peter J. Shaw,Rammurti T. Kamble,Raquel Schears,Richard F. Olsson,Robert J. Hayashi,Robert Peter Gale,Samantha J. Mayo,Saurabh Chhabra,Seth J. Rotz,Sherif M. Badawy,Siddhartha Ganguly,Steven Pavletic,Taiga Nishihori,Tim Prestidge,Vaibhav Agrawal,William J. Hogan,Yoshihiro Inamoto,Bronwen E. Shaw,Prakash Satwani
COMMENTARIES
ERRATA
-
Cover Image
Cover Image
COVER FIGURE
Interactions between CD27, varlilumab, and the antigen-specific T-cell receptor (TCR) in the immune activation of effector T cells. APC, antigen-presenting cell; MHC, major histocompatibility complex. See the article by Ansell et al. - PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals